



**30th Annual Cancer Progress Conference
May 7-8, 2019
Convene, 32 Old Slip, NYC**

May 7, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks

Jeffrey M. Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

8:15 – 9:15am

Keynote: Realizing the full potential of CRISPR for cancer therapies and other precision medicines

Rachel Haurwitz, PhD, Chief Executive Officer and Founder, Caribou

9:15 – 10:30am

Has the Time Come for Chemo- & Immuno- Prevention: Nixing the Nabobs of Negativity

Moderator:

Panelists

- John Letterio, MD, Division Chief, Pediatric Hematology and Oncology, UH Cleveland Medical Center Division Chief, Pediatric Hematology and Oncology, UH Rainbow Babies and Children's Hospital Professor, Pediatrics, CWRU School of Medicine Interim Director, UH Seidman Cancer Center
- Michael B. Sporn, MD, Professor of Pharmacology and Medicine/Molecular and Systems Biology/Active Emeritus, Dartmouth Medical School
- William C. Watt, PhD, President and Chief Executive Officer, EpiThany

10:30 – 11:00am

Networking Break

11:00 – 12:15pm

Novel Ways to Target and Develop Therapies for Cancer Metastases: Stop Spreading the New

Moderator:

Panelists:

- Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of Molecular Biology, Princeton University
- Tim van Hauwermeiren, MSc., MBA, Chief Executive Officer, arGEN-X
- Maurice Zauderer, PhD, President & Chief Executive Officer, Vaccinex, Inc.
- TBD, Vuja De

12:15 – 1:30pm

Networking Luncheon

Keynote Luncheon Speaker

Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.





1:30 – 2:45pm

Basket Trials Revisited: Faster, Better, Smarter Trials/Precision Medicine: Insights and Remaining Challenges, Perspectives from Academia, Pharma and Biotech

Moderator

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute

Panelists

- Peter J. O'Dwyer, MD, Group Co-Chair, ECOG-ACRIN Cancer Research Group; Abramson Cancer Center, University of Pennsylvania
- Richard L. Schilsky, MD, FACP, FSCT, FASCO, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology

2:45 – 3:15pm

Networking Break

3:15 – 4:30pm

IO Session I: Combination Failures & Futures: Much Ado About What?

Moderator: Jeff Bockman, PhD, Executive Vice President, Head of Oncology Practice, Defined Health

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Robert Stein, MD, PhD, Senior R&D Advisor, Agenus
- Mai-Britt Zocca, MD, PhD, MBA, Chief Executive Officer, IO Biotech

5:00 – 7:00pm

Cancer Progress 2019 Reception

May 8, 2019

7:00 – 8:00am

Registration and Continental Breakfast

8:00 – 8:15am

Opening Remarks: Review of Day 1

Mike Rice, MS, MBA, Principal, Defined Health



8:15 – 9:30am

Payer/Access Panel

Moderator: Ed Saltzman, Executive Chairman, Defined Health

Panelists

- Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Roger Longman, Chief Executive Officer, Real Endpoints
- Burt Zweigenhaft, Managing Partner, Upstream Partners Inc.

9:30 – 10:45 am

IO Session II: IO Targets and Platforms- Target Versus Modality- What Are the Keys to the Kingdom?

Moderator: Joel Sandler, PhD, Associate Principal, Defined Health

Panelists

- Ramy Ibrahim, MD, Vice President and Head of Research & Development, Parker Institute
- Louis Matis, MD, SVP and Chief Development Officer, Pieris Pharmaceuticals
- Dan Shoemaker, PhD, CSO, Fate Therapeutics
- Harpreet Singh, PhD, Chief Scientific Officer and Managing Director, Immatics Biotechnologies

10:45 – 11:15am

Networking Break

11:15am – 12:30pm

Gynecological & Breast Cancers, Much Progress, Much to Do: How Novel Therapies from PARPs to Immunotherapies Are Transforming Care

Moderator

Panelists

- Brian Leyland Jones, MBBS, PhD, VP, Avera Cancer Institute Center for Precision Onc & Dept of Molecular & Experimental Medicine, Avera Cancer Institute
- Dmitriy Zamarin, MD, PhD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
- Lajos Pusztai, MD, D Phil., Yale, Director Breast Cancer Translational Research

12:30 – 1:45pm

Biotech Deal-Making in the Face of IO Frenzy or Fatigue: Same Old or Difference New?

Moderator

Panelists

- Kapil Dhingra, MD, Managing Member, KAPital Consulting LLC
- John Haurum, MD, PhD, Chief Executive Officer, f-Star Biotech
- Axel Hoos, MD, PhD, SVP Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
- Annette Matthies, PhD, Vice President, Corporate Development, EFFECTOR Therapeutics
- Helen Tayton-Martin, PhD, MBA, Chief Business Officer, Adaptimmune





1:45 – 3:00pm

Networking Lunch

3:00– 4:15pm

Insights from Heme Malignancies – Making Breakthrough Conventional and Unconventional Therapies Accessible Beyond Niche Blood Cancer Patients

Moderator: Mike Rice, MS, MBA, Principal, Defined Health

Panelists

- Michael Kalos, MD, JNJ, Vice President Immunology & Oncology Cellular Therapies
- Adi Hoess, CEO of Affimed
- Fate Therapeutics

4:15 – 5:30pm

Oncology Innovation Powered by Investments and Competition from China

Moderator: James Lee, PhD, Associate Principal, Oncology Lead, Defined Health

Panelists

- Ji Li, PhD, Venture Partner, Lilly Asia Ventures
- Weimin Tang, PhD, Executive Vice President and Global Business Head, I-Mab Biopharma
- Garry Menzel, President and CEO, TCR² Therapeutics
- Jack Wu, PhD, Adlai Nortye, Head of Business Development

5:30 pm

Cancer Progress 2019 Conference Concludes